Most B-ALL patients who relapse after CD19 CAR T-cell therapy had no response to reinfusion of CD19 CAR T cells, even when CD19 expression is positive (31). This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.